126 related articles for article (PubMed ID: 19353351)
21. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.
Yawn BP; Raphiou I; Hurley JS; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2010 Jun; 5():165-78. PubMed ID: 20631816
[TBL] [Abstract][Full Text] [Related]
22. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
23. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
Terzano C; Petroianni A; Ricci A; Allegra L
Eur Rev Med Pharmacol Sci; 2005; 9(4):209-15. PubMed ID: 16128040
[TBL] [Abstract][Full Text] [Related]
25. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular events in patients with COPD: TORCH study results.
Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Crim C; Willits LR; Yates JC; Vestbo J;
Thorax; 2010 Aug; 65(8):719-25. PubMed ID: 20685748
[TBL] [Abstract][Full Text] [Related]
27. [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)].
Corhay JL; Louis R
Rev Med Liege; 2007 Apr; 62(4):230-4. PubMed ID: 17566394
[TBL] [Abstract][Full Text] [Related]
28. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
MMW Fortschr Med; 2003 Nov; 145(46):47. PubMed ID: 14699834
[No Abstract] [Full Text] [Related]
29. Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?
Gillissen A
Am J Respir Crit Care Med; 2008 Jul; 178(1):105; author reply 106-7. PubMed ID: 18565963
[No Abstract] [Full Text] [Related]
30. Management of patients with COPD: a comparison of the INSPIRE and TORCH studies.
Middleton PG
Am J Respir Crit Care Med; 2008 Jul; 178(1):106; author reply 106-7. PubMed ID: 18565964
[No Abstract] [Full Text] [Related]
31. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
[TBL] [Abstract][Full Text] [Related]
32. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.
Dransfield MT; Bailey WC
Expert Opin Pharmacother; 2004 Aug; 5(8):1815-26. PubMed ID: 15264996
[TBL] [Abstract][Full Text] [Related]
33. Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD.
Andò F; Ruggeri P; Girbino G; Cazzola M
Respir Med; 2008 Jun; 102(6):815-8. PubMed ID: 18343646
[TBL] [Abstract][Full Text] [Related]
34. Fluticasone/salmeterol: labeling change.
Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
[TBL] [Abstract][Full Text] [Related]
35. [Chronic obstructive pulmonary disease. No increased survival with combination therapy].
Ecker-Schlipf B
Med Monatsschr Pharm; 2007 Nov; 30(11):428-9. PubMed ID: 18062342
[No Abstract] [Full Text] [Related]
36. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
Dahl R; Chuchalin A; Gor D; Yoxall S; Sharma R
Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212
[TBL] [Abstract][Full Text] [Related]
37. [Inhaled corticosteroids in patients with COPD: maintain current guidelines].
Heijdra YF
Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2195-7. PubMed ID: 17969568
[TBL] [Abstract][Full Text] [Related]
38. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.
Kunisaki KM; Rice KL; Janoff EN; Rector TS; Niewoehner DE
Ther Adv Respir Dis; 2008 Apr; 2(2):55-64. PubMed ID: 19124359
[TBL] [Abstract][Full Text] [Related]
39. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
40. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
